CA3072854A1 - Tetrazole compounds and their use in the treatment of tuberculosis - Google Patents
Tetrazole compounds and their use in the treatment of tuberculosis Download PDFInfo
- Publication number
- CA3072854A1 CA3072854A1 CA3072854A CA3072854A CA3072854A1 CA 3072854 A1 CA3072854 A1 CA 3072854A1 CA 3072854 A CA3072854 A CA 3072854A CA 3072854 A CA3072854 A CA 3072854A CA 3072854 A1 CA3072854 A1 CA 3072854A1
- Authority
- CA
- Canada
- Prior art keywords
- tetrazol
- benzenesulfonamide
- hydroxyethyl
- methyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382574 | 2017-08-17 | ||
| EP17382574.6 | 2017-08-17 | ||
| PCT/EP2018/072205 WO2019034729A1 (en) | 2017-08-17 | 2018-08-16 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3072854A1 true CA3072854A1 (en) | 2019-02-21 |
Family
ID=59713960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3072854A Pending CA3072854A1 (en) | 2017-08-17 | 2018-08-16 | Tetrazole compounds and their use in the treatment of tuberculosis |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11072591B2 (https=) |
| EP (1) | EP3668856B1 (https=) |
| JP (1) | JP7410017B2 (https=) |
| KR (1) | KR102661367B1 (https=) |
| CN (1) | CN110997651B (https=) |
| AU (1) | AU2018317812C1 (https=) |
| CA (1) | CA3072854A1 (https=) |
| CY (1) | CY1124577T1 (https=) |
| DK (1) | DK3668856T3 (https=) |
| ES (1) | ES2885573T3 (https=) |
| HR (1) | HRP20211326T1 (https=) |
| HU (1) | HUE055732T2 (https=) |
| LT (1) | LT3668856T (https=) |
| PL (1) | PL3668856T3 (https=) |
| PT (1) | PT3668856T (https=) |
| RS (1) | RS62267B1 (https=) |
| SI (1) | SI3668856T1 (https=) |
| SM (1) | SMT202100515T1 (https=) |
| WO (1) | WO2019034729A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111184718A (zh) * | 2018-11-15 | 2020-05-22 | 鲁南制药集团股份有限公司 | 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途 |
| CN115403533B (zh) * | 2021-05-28 | 2023-08-25 | 永康市第一人民医院 | 一种1-苯乙烯基-1,2,3-三氮唑化合物及其制备方法和应用 |
| CN116102483B (zh) * | 2021-11-09 | 2025-01-17 | 中国医学科学院药物研究所 | 取代吡咯-2,5-二酮类化合物及其制备方法和用途 |
| CN116726018A (zh) * | 2023-08-02 | 2023-09-12 | 上海市肺科医院（上海市职业病防治院） | 一种贝达喹啉、德拉马尼、氯法齐明和吡嗪酰胺的联用和应用 |
| CN117379430A (zh) * | 2023-10-11 | 2024-01-12 | 深圳市第三人民医院(深圳市肝病研究所) | 一种地拉韦啶的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3621427B2 (ja) | 1997-07-22 | 2005-02-16 | 塩野義製薬株式会社 | 糸球体障害治療または予防剤 |
| KR20120003499A (ko) * | 2007-04-05 | 2012-01-10 | 지멘스 메디컬 솔루션즈 유에스에이, 인크. | 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조 |
| WO2017066964A1 (en) | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
-
2018
- 2018-08-16 WO PCT/EP2018/072205 patent/WO2019034729A1/en not_active Ceased
- 2018-08-16 ES ES18755815T patent/ES2885573T3/es active Active
- 2018-08-16 HR HRP20211326TT patent/HRP20211326T1/hr unknown
- 2018-08-16 US US16/639,163 patent/US11072591B2/en active Active
- 2018-08-16 PT PT187558150T patent/PT3668856T/pt unknown
- 2018-08-16 JP JP2020508427A patent/JP7410017B2/ja active Active
- 2018-08-16 SM SM20210515T patent/SMT202100515T1/it unknown
- 2018-08-16 EP EP18755815.0A patent/EP3668856B1/en active Active
- 2018-08-16 CN CN201880053320.XA patent/CN110997651B/zh active Active
- 2018-08-16 CA CA3072854A patent/CA3072854A1/en active Pending
- 2018-08-16 LT LTEPPCT/EP2018/072205T patent/LT3668856T/lt unknown
- 2018-08-16 SI SI201830348T patent/SI3668856T1/sl unknown
- 2018-08-16 PL PL18755815T patent/PL3668856T3/pl unknown
- 2018-08-16 RS RS20211076A patent/RS62267B1/sr unknown
- 2018-08-16 AU AU2018317812A patent/AU2018317812C1/en active Active
- 2018-08-16 KR KR1020207007186A patent/KR102661367B1/ko active Active
- 2018-08-16 DK DK18755815.0T patent/DK3668856T3/da active
- 2018-08-16 HU HUE18755815A patent/HUE055732T2/hu unknown
-
2021
- 2021-08-31 CY CY20211100770T patent/CY1124577T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3668856B1 (en) | 2021-06-23 |
| WO2019034729A1 (en) | 2019-02-21 |
| BR112020003247A2 (pt) | 2020-08-18 |
| JP2020531425A (ja) | 2020-11-05 |
| ES2885573T3 (es) | 2021-12-14 |
| CN110997651A (zh) | 2020-04-10 |
| SMT202100515T1 (it) | 2021-11-12 |
| PL3668856T3 (pl) | 2021-12-13 |
| CY1124577T1 (el) | 2022-07-22 |
| RU2020110818A (ru) | 2021-09-17 |
| EP3668856A1 (en) | 2020-06-24 |
| US20200231555A1 (en) | 2020-07-23 |
| RS62267B1 (sr) | 2021-09-30 |
| US11072591B2 (en) | 2021-07-27 |
| KR20200041915A (ko) | 2020-04-22 |
| JP7410017B2 (ja) | 2024-01-09 |
| HRP20211326T1 (hr) | 2021-11-26 |
| CN110997651B (zh) | 2023-01-03 |
| PT3668856T (pt) | 2021-09-15 |
| AU2018317812B2 (en) | 2021-04-15 |
| DK3668856T3 (da) | 2021-09-20 |
| HUE055732T2 (hu) | 2021-12-28 |
| RU2020110818A3 (https=) | 2021-10-11 |
| AU2018317812A1 (en) | 2020-02-20 |
| AU2018317812C1 (en) | 2021-08-26 |
| KR102661367B1 (ko) | 2024-04-29 |
| SI3668856T1 (sl) | 2021-11-30 |
| LT3668856T (lt) | 2021-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10709712B2 (en) | Biaryl amide compounds as kinase inhibitors | |
| EP3191478B1 (en) | Compounds and compositions as raf kinase inhibitors | |
| EP3668856B1 (en) | Novel tetrazole compounds and their use in the treatment of tuberculosis | |
| EP3191472B1 (en) | Compounds and compositions as raf kinase inhibitors | |
| JP6308504B2 (ja) | タンパク質キナーゼ阻害薬 | |
| TW201249823A (en) | Tetrasubstituted cyclohexyl compounds as kinase inhibitors | |
| JP6646044B2 (ja) | キナーゼ阻害剤としての化合物および組成物 | |
| EP2411368A1 (fr) | Derives de nicotinamide, leur preparation et leur application en therapeutique comme anticancereux | |
| TW202116754A (zh) | 作為ｌｒｒｋ２抑制劑之吲唑及氮雜吲唑 | |
| CA2887887A1 (en) | Pyrazolopyridine derivatives as ttx-s blockers | |
| KR20220122649A (ko) | 신규한 약학 조성물(new pharmaceutical compounds) | |
| RU2800930C2 (ru) | Новые производные тетразола и их применение в лечении туберкулеза | |
| TW202023548A (zh) | 新穎噻唑衍生物以及其藥用可接受鹽類 | |
| BR112020003247B1 (pt) | Compostos de tetrazol, uso dos ditos compostos para o tratamento de infecção micobacteriana ou de doença causada pela mesma, composição farmacêutica e combinação que compreende os compostos | |
| RU2801140C2 (ru) | Соединения азалактама в качестве ингибиторов hpk1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230811 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240924 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250217 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20250422 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250724 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250822 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250826 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251222 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260119 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260119 |